**Supplementary Table-1 *-* Main features per group of participants**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | Non-Oncology | Non-Oncology  + Cannabis use | Oncology | Oncology  + Cannabis use | | p-value |
|  |  | n = 46 | n = 21 | n = 62 | n = 25 |  | |
| Time from vaccination to test [Days] (mean (SD)) | - | 78.46 (18.97) | 83.90 (23.79) | 68.11 (15.76) | 70.80 (19.15) | .003a | |
| IgG (mean (SD)) | - | 13,190.63 (11,562.85) | 12,825.93 (12,172.65) | 14,813.24 (14,414.52) | 13,069.02 (11,056.11) | .874a | |
| IgG response, n (%) | IgG<4000 | 8 ( 17.4) | 5 ( 23.8) | 18 ( 29.0) | 5 ( 20.0) | .534b | |
|  | IgG>4000 | 38 ( 82.6) | 16 ( 76.2) | 44 ( 71.0) | 20 ( 80.0) |  | |
| Gender, n (%) | Female | 25 ( 54.3) | 13 ( 61.9) | 37 ( 59.7) | 10 ( 40.0) | .357b | |
|  | Male | 21 ( 45.7) | 8 ( 38.1) | 25 ( 40.3) | 15 ( 60.0) |  | |
| Age (mean (SD)) | - | 58.63 (14.38) | 53.76 (14.54) | 65.68 (11.25) | 63.72 (13.30) | .001a | |
| Cancer type, n (%) | Bladder | - | - | 2 ( 3.2) | 0 ( 0.0) | .271b | |
|  | Breast | - | - | 24 ( 38.7) | 6 ( 24.0) |  | |
|  | Colon | - | - | 7 ( 11.3) | 4 ( 16.0) |  | |
|  | Kidney | - | - | 1 ( 1.6) | 1 ( 4.0) |  | |
|  | Lungs | - | - | 4 ( 6.5) | 4 ( 16.0) |  | |
|  | Lymphoma | - | - | 3 ( 4.8) | 1 ( 4.0) |  | |
|  | Melanoma | - | - | 8 ( 12.9) | 1 ( 4.0) |  | |
|  | Pancreas | - | - | 1 ( 1.6) | 2 ( 8.0) |  | |
|  | Prostate | - | - | 1 ( 1.6) | 0 ( 0.0) |  | |
|  | Sarcoma | - | - | 0 ( 0.0) | 2 ( 8.0) |  | |
|  | Stomach | - | - | 6 ( 9.7) | 2 ( 8.0) |  | |
|  | Urinary bladder | - | - | 3 ( 4.8) | 2 ( 8.0) |  | |
|  | Uterus | - | - | 2 ( 3.2) | 0 ( 0.0) |  | |
| Cancer stage, n (%) | Localized | - | - | 20 ( 32.3) | 7 ( 28.0) | .894b | |
|  | Metastatic | - | - | 42 ( 67.7) | 18 ( 72.0) |  | |
| Treatment, n (%) | Biological | - | - | 6 ( 9.7) | 1 ( 4.0) | .684b | |
|  | Chemo | - | - | 31 ( 50.0) | 16 ( 64.0) |  | |
|  | Chemo + Biological | - | - | 7 ( 11.3) | 4 ( 16.0) |  | |
|  | Chemo + Immunotherapy | - | - | 3 ( 4.8) | 1 ( 4.0) |  | |
|  | Hormonal | - | - | 7 ( 11.3) | 1 ( 4.0) |  | |
|  | Immunotherapy | - | - | 8 ( 12.9) | 2 ( 8.0) |  | |
| THC\* vs CBD\*\* cannabis type [users per type] n (%) | CBD rich | - | 5 ( 23.8) | - | 7 ( 28.0) | .747b | |
|  | THC rich | - | 16 ( 76.2) | - | 18 ( 72.0) |  | |
| Cannabis use [gr/month]  (mean (SD)) | - | - | 32.38 (14.80) | - | 28.40 (18.64) | .433a | |
| Cannabis sessions per day  (mean (SD)) | - | - | 1.19 (0.40) | - | 1.16 (0.37) | .818a | |

(a) = t-test; (b) = chi-squared test; (\*)Tetrahydrocannabinol (THC); (\*\*) Cannabidiol (CBD)